Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intra Cranial EEG Activity During Dexmedetomidine Sedation

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by University Health Network, Toronto.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT01648959
First received: July 13, 2012
Last updated: July 23, 2012
Last verified: July 2012
  Purpose

Various parts of the brain are sensitive to various anesthetics.We like to study the effect of dexmedetomidine on the different parts of the brain in patients who are coming for DBS electrode removal under sedation.


Condition
EEG Effect of Dexmedetomidine on the Cortical and Subcortical Structures

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Intra Cranial EEG Activity During Dexmedetomidine Sedation.Comparing the Effects of Dexmedetomidine on the Cortical and the Sub Cortical(Hippocampus) Structures.

Resource links provided by NLM:


Further study details as provided by University Health Network, Toronto:

Estimated Enrollment: 20
Study Start Date: July 2012
Estimated Study Completion Date: May 2014
Estimated Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Detailed Description:

Cortical and sub cortical structures will have different sensitivities to various anesthetics.The objective of this study is to look at the changes in the intracranial electroencephalographic (EEG) characteristics during dexmedetomidine sedation and to determine the differences in the EEG characteristics between cortical and subcortical structures.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Adults between 18 to 80 years of age, who are scheduled for elective removal of intracranial (surface and depth) electrodes under conscious sedation

Criteria

Inclusion Criteria:

  • Adults between 18 to 80 years of age, who are scheduled for elective removal of intracranial (surface and depth) electrodes under conscious sedation

Exclusion Criteria:

  • Lack of informed consent
  • Hypersensitivity to dexmedetomidine
  • Language barrier
  • Emergency surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01648959

Contacts
Contact: Lashmikumar venkatraghavan, MD 416-603 ext 5800 Lashmi.Venkatraghavan@uhn.ca
Contact: Pirjo Manninen, MD 416-603 ext 5118 Prijo.Manninen@uhn.ca

Locations
Canada, Ontario
Toronto Western Hospital,UHN. Not yet recruiting
Toronto, Ontario, Canada, M5T2S8
Contact: Lashmi kumar venkatraghavan, MD    416-603 ext 5800    Lashmi.Venkatraghavan@uhn.ca   
Contact: Pirjo Manninen, MD    416-603 ext 5118    Pirjo.Manninen@uhn.ca   
Sub-Investigator: Ramamani Mariappan, MD         
Sub-Investigator: Taufik Valiante, MD,PhD         
Sub-Investigator: Pirjo Manninen, MD         
Principal Investigator: Lashmikumar Venkatraghavan, MD         
Sponsors and Collaborators
University Health Network, Toronto
Investigators
Principal Investigator: lashmikumar venkatraghavan, MD Assistant professor,Toronto western hospital,university health network (UHN)
  More Information

No publications provided

Responsible Party: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT01648959     History of Changes
Other Study ID Numbers: 12-0268-B
Study First Received: July 13, 2012
Last Updated: July 23, 2012
Health Authority: Canada:University Health Network, Toronto.ON.

Additional relevant MeSH terms:
Dexmedetomidine
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Analgesics
Analgesics, Non-Narcotic
Central Nervous System Agents
Central Nervous System Depressants
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014